Fulcrum Therapeutics Inc
FULC
Get informed when a big investor buys or sells
+ FollowMarket Cap$292.22M
Close$
$3.02
21.9% downside
Current Fair Value
21.9% downsideOvervalued by 21.9% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $292.22 Million |
|---|---|
| Enterprise Value | $249.03 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-1.18 |
| Beta | 3 |
| Outstanding Shares | 76,264,000 |
Return
| Return on Equity | -27.36% |
|---|---|
| Return on Assets | -26.24% |
| Return on Invested Capital | -29.87% |
Valuation & Multiples
| P/E Ratio | -3.17 |
|---|---|
| PEG | -6.16 |
| Price to Sales | - |
| Price to Book Ratio | 0.97 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -2.66 |
| Enterprise Value to Net Income | -3 |
| Total Debt to Enterprise | 0.02 |
| Debt to Equity | 0.02 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 5, 2026
EPS Estimate
$-0.29
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
October 29, 2026
EPS Estimate
$-0.13
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.2490▼ 68.76% |
|---|---|
| Total Calls | 571,000▲ 146.12% |
| Total Puts | 142,200▼ 34.56% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 113.20%▲ 6.74% |
|---|---|
| Total Invested | $550.14M▼ 27.87% |
| Investors Holding | 175▼ 3.00% |
ESG Score
No data
About Fulcrum Therapeutics Inc
73 employeesFulcrum Therapeutics is a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases in areas of high unmet medical need. Fulcrum's proprietary product engine identifies dru...